PGEN

Precigen Inc · NASDAQ

Sector Health Technology
Industry Biotechnology
Website recigen.com
Employees(FY) 209
ISIN US74017N1054

Performance

-11.89%

-12.21%

-27.24%

-39.37%

-37.56%

YTD

-30.85%

Profile

Precigen, Inc. operates as a discovery and clinical stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company, through its technologies, enables to find solutions for biotherapeutics. The company operates as an engine progressing a preclinical and clinical pipeline of therapies toward clinical proof-of-concept and commercialization. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Advanced Technical Analysis

Technical Analysis of PGEN 2024-11-20

The stock indicators reflect a bearish sentiment overall, with a Moving Average Score of 10 indicating strong downward momentum, an Oscillators Score of 43 suggesting a neutral stance, and a Technical Score of 26 reinforcing the bearish outlook. This combination points to a challenging environment for the stock, with potential for further declines.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of PGEN

Stock Rank

Recent News & Updates

2024-11-14 03:30
Precigen Reports Third Quarter 2024 Financial Results and Business Updates(Prnewswire)
2024-11-12 03:05
Precigen to Participate in the Stifel 2024 Healthcare Conference(Prnewswire)
2024-09-16 04:30
Precigen to Participate in the 2024 Cantor Global Healthcare Conference(Prnewswire)
2024-08-14 04:05
Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates(Prnewswire)
2024-08-14 01:54
Hedge Fund and Insider Trading News: Nelson Peltz, Jana Partners, Whitebox Advisors, Caxton Associates LP, Altium Capital, Soros Fund Management, Elliott Investment Management, Balyasny Asset Management, Precigen Inc (PGEN), Vulcan Materials Company (VMC),(Insidermonkey)
2024-08-08 20:00
Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th(Prnewswire)
2024-08-07 09:30
Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock(Prnewswire)
2024-08-06 04:04
Precigen Announces Proposed $30 Million Public Offering of Common Stock(Prnewswire)
2024-08-06 04:01
Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch(Prnewswire)
2024-07-22 20:01
Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch(Prnewswire)
2024-06-02 21:30
Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response(Prnewswire)
2024-05-23 05:00
Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting(Prnewswire)
2024-05-14 05:20
Precigen, Inc. (PGEN) Reports Q1 Loss, Misses Revenue Estimates(Zacks)
2024-05-14 04:05
Precigen Reports First Quarter 2024 Financial Results and Business Updates(Prnewswire)
2024-05-13 20:21
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q1 2024 Earnings Call Transcript(Insidermonkey)
2024-05-08 04:05
Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting(Prnewswire)
2024-04-23 22:20
Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting(Prnewswire)
2024-04-23 21:00
Actym Therapeutics Appoints Thomas Smart as CEO(Prnewswire)
2024-03-28 04:05
Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th(Prnewswire)
2024-03-26 20:20
Analysts on Wall Street Lower Ratings for These 10 Stocks(Insidermonkey)
2024-03-19 22:07
Precigen, Inc. (NASDAQ:PGEN) Q4 2023 Earnings Call Transcript(Insidermonkey)
2024-03-19 08:53
PGEN Stock Earnings: Precigen Misses EPS, Misses Revenue for Q4 2023(Investorplace)
2024-03-19 05:31
Precigen Inc (PGEN) Reports Full Year 2023 Financial Results(Yahoo Finance)
2024-03-19 04:05
Precigen Reports Full Year 2023 Financial Results and Business Updates(Prnewswire)
2024-03-12 04:05
Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis(Prnewswire)
2024-03-05 03:05
Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th(Prnewswire)
2024-02-06 03:05
Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference(Prnewswire)
2024-01-15 19:05
Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission(Prnewswire)
2024-01-07 19:30
Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference(Prnewswire)
2024-01-01 23:40
Hedge Fund and Insider Trading News: David Einhorn, Bill Ackman, D. E. Shaw, Steve Cohen, Rob Citrone, Saba Capital, HighPeak Energy, Inc (HPK), Precigen Inc (PGEN), and More(Insidermonkey)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.